Cencora, Inc. (COR)

Cencora posts strong revenue expansion approaching the $300 billion mark, largely supported by an increased volume of higher-priced specialty drugs and its crucial role in global drug distribution.

As one of the Big Three pharmaceutical distributors, Cencora maintains its oligopoly position effectively. Its market share is well protected, making slow but steady gains globally.

Pricing power is intrinsically limited due to the nature of drug distribution and negotiation pressures from large buyers and government entities, though scale provides some buffer.

Its velocity relies on expanding distribution capabilities, integrating technology, and acquiring high-margin specialty services rather than traditional product innovation.

Once integrated into a healthcare provider's or pharmacy's supply chain, switching distributors introduces massive operational risk, leading to incredible client retention.

Its vast logistics network connects numerous manufacturers with countless points of care. The scale of this network creates incredible density and efficiency that new entrants cannot replicate.

Operating within a heavily regulated space creates high barriers to entry, though it exposes the company to risks of shifting healthcare policies and pricing legislations.

Despite the massive physical infrastructure required, Cencora's massive revenue base makes capital expenditures relatively small as a percentage of sales, allowing for strong cash conversion.

Earnings estimates have remained resilient and often see positive revisions as the volume of expensive specialty and complex therapeutics continues to expand.

The narrative remains positive, focusing on the company's defensive qualities amidst macroeconomic uncertainty and its ongoing expansion in global markets.

Management has effectively utilized free cash flow for strategic acquisitions in higher-margin businesses, alongside consistent dividend growth and share repurchases.